Inventor · disambiguated record
Margaret Karow
Also filed as: KAROW MARGARET · KAROW MARGARET LEE
72 granted patents·22 pending applications·1,233 citations·filing 2001–2025
99Inventor score
Top patents by PatentIndex Score
94 records- 0199US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 0299US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 0399US7396664B2VEGF-binding fusion proteins and nucleic acids encoding the sameREGENERON PHARMA·Filed 2005·Granted Jul 8, 2008·171 cites·11 claims
- 0498US10694725B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Jun 30, 2020·15 cites·16 claims
- 0598US10577430B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Mar 3, 2020·15 cites·16 claims
- 0698US8791323B2Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouseMURPHY ANDREW J·Filed 2006·Granted Jul 29, 2014·97 cites·3 claims
- 0797US10905109B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Feb 2, 2021·10 cites·13 claims
- 0897US10072095B2ADAM6 miceREGENERON PHARMA·Filed 2015·Granted Sep 11, 2018·14 cites·23 claims
- 0997US9580486B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2014·Granted Feb 28, 2017·47 cites·27 claims
- 1096US10905108B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Feb 2, 2021·6 cites·12 claims
- 1196US10542735B2Humanized non-human animals with restricted immunoglobulin heavy chain lociREGENERON PHARMA·Filed 2018·Granted Jan 28, 2020·6 cites·26 claims
- 1296US9932380B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2017·Granted Apr 3, 2018·23 cites·23 claims
- 1396US9884916B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2016·Granted Feb 6, 2018·13 cites·7 claims
- 1495US11666040B2Humanized non-human animals with restricted immunoglobulin heavy chain lociREGENERON PHARMA·Filed 2020·Granted Jun 6, 2023·3 cites·46 claims
- 1595US11053294B2Masked cytokine polypeptidesXILIO DEV INC·Filed 2020·Granted Jul 6, 2021·13 cites·15 claims
- 1695US10130081B2Humanized universal light chain miceMCWHIRTER JOHN·Filed 2012·Granted Nov 20, 2018·21 cites·19 claims
- 1795US9708635B2Methods of making a nucleic acid encoding a human variable regionREGENERON PHARMA·Filed 2012·Granted Jul 18, 2017·9 cites·10 claims
- 1895US7666622B2Monomeric self-associating fusion polypeptides and therapeutic uses thereofREGENERON PHARMA·Filed 2006·Granted Feb 23, 2010·56 cites·12 claims
- 1994US11950578B2ADAM6 miceREGENERON PHARMA·Filed 2020·Granted Apr 9, 2024·2 cites·14 claims
- 2094US11357217B2Humanized universal light chain miceREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Jun 14, 2022·7 cites·25 claims
- 2194US10829535B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2018·Granted Nov 10, 2020·5 cites·5 claims
- 2294US10640800B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2016·Granted May 5, 2020·4 cites·6 claims
- 2394US9388446B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jul 12, 2016·6 cites·8 claims
- 2494US8192741B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2011·Granted Jun 5, 2012·22 cites·10 claims
- 2593US11559050B2Humanized non-human animals with restricted immunoglobulin heavy chain lociREGENERON PHARMA·Filed 2019·Granted Jan 24, 2023·4 cites·22 claims
- 2693US9353394B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted May 31, 2016·6 cites·7 claims
- 2793US8568721B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2012·Granted Oct 29, 2013·18 cites·9 claims
- 2893US2025206829A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2992US11866476B2Masked IL-2-Fc fusion polypeptidesXILIO DEV INC·Filed 2022·Granted Jan 9, 2024·1 cites·10 claims
- 3092US9528136B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2013·Granted Dec 27, 2016·5 cites·9 claims
- 3192US9371553B2Genetically modified mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jun 21, 2016·6 cites·5 claims
- 3292US8183014B2High affinity antibodies to human IL-6 receptorSTEVENS SEAN·Filed 2011·Granted May 22, 2012·11 cites·19 claims
- 3392US7083950B2High affinity fusion proteins and therapeutic and diagnostic methods for useREGENERON PHARMA·Filed 2003·Granted Aug 1, 2006·26 cites·14 claims
- 3491US10851157B2Antagonists targeting the TGF-β pathwayGENSUN BIOPHARMA INC·Filed 2019·Granted Dec 1, 2020·5 cites·34 claims
- 3591US10378040B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·4 cites·4 claims
- 3691US9308256B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·11 cites·14 claims
- 3791US8080248B2Method of treating rheumatoid arthritis with an IL-6R antibodyRADIN ALLEN·Filed 2010·Granted Dec 20, 2011·15 cites·11 claims
- 3891US2024306617A1Adam6 miceREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3991US2025361306A1Antitumor immune checkpoint regulator antagonistsGENSUN BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 4090US11718655B2Masked interleukin-12 polypeptidesXILIO DEV INC·Filed 2022·Granted Aug 8, 2023·1 cites·9 claims
- 4190US9376699B2Methods of producing hybrid antibodiesMURPHY ANDREW J·Filed 2011·Granted Jun 28, 2016·4 cites·8 claims
- 4289US11001635B2Antitumor antagonistsGENSUN BIOPHARMA INC·Filed 2019·Granted May 11, 2021·2 cites·4 claims
- 4389US10526630B2Genetically modified mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jan 7, 2020·3 cites·2 claims
- 4489US10378037B2Methods of making a nucleic acid encoding a human variable regionREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·10 claims
- 4589US10378039B2Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locusREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·4 claims
- 4689US10378038B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·3 claims
- 4789US10227625B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2012·Granted Mar 12, 2019·3 cites·3 claims
- 4888US11976133B2Bispecific T cell engagersGENSUN BIOPHARMA INC·Filed 2021·Granted May 7, 2024·2 cites·10 claims
- 4988US2024327485A1Interleukin-2 muteins for the expansion of t-regulatory cellsAMGEN INC·Filed 2024·Application pending·0 cites
- 5087US12404336B2Bispecific antagonist comprising a LAG-3 binding domainGENSUN BIOPHARMA INC·Filed 2023·Granted Sep 2, 2025·0 cites·20 claims
Showing the top 50 of 94 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Margaret Karow files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →